Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Report 2026

Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Overview

• Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery market size has reached to $8.46 billion in 2025 • Expected to grow to $15.22 billion in 2030 at a compound annual growth rate (CAGR) of 12.5% • Growth Driver: The Rising Demand For Personalized Medicine Driving The Growth Of The Market Due To Advancements In Genomics And Targeted Therapies • Market Trend: Innovations In DNA Sequencing Technologies Accelerate Target Identification And Validation In Drug Discovery • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market?

Deoxyribonucleic acid (DNA) sequencing in drug discovery is the process of determining the precise order of nucleotides in genetic material to understand disease mechanisms at a molecular level. It enables researchers to identify genetic mutations, biomarkers, and therapeutic targets that influence disease progression and drug response. By providing detailed genomic insights, DNA sequencing supports the design of more precise, effective, and personalized drug candidates. The main product types of deoxyribonucleic acid (DNA) sequencing in drug discovery include instruments and consumables. Instruments refer to laboratory devices used to perform sequencing experiments and analyze genetic material for drug discovery applications. These sequencing methods are used in workflows such as sample preparation and sequencing. The technology types include Sanger sequencing and next-generation sequencing. The applications include drug discovery and pharmacogenomics, and the end users are pharmaceutical companies and biotechnology firms.

What Is The Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Growth Forecast?

The deoxyribonucleic acid (dna) sequencing in drug discovery market size is expected to see rapid growth in the next few years. It will grow to $15.22 billion in 2030 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to increasing adoption of AI-driven genomic analysis, rising demand for targeted therapeutics, expansion of pharmacogenomics applications, growing use of sequencing in early-stage drug screening, increasing collaboration between pharma and biotech firms. Major trends in the forecast period include increasing use of next-generation sequencing in target identification, rising adoption of single-cell sequencing approaches, growing integration of bioinformatics in drug discovery, expansion of precision medicine research programs, enhanced focus on biomarker-driven drug development.

Global Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Segmentation

1) By Product Type: Instruments; Consumables 2) By Workflow: Sample Preparation; Sequencing 3) By Technology Type: Sanger Sequencing; Next-Generation Sequencing (NGS) 4) By Application: Drug Discovery; Pharmacogenomics 5) By End-User: Pharmaceutical Companies; Biotechnology Firms Subsegments: 1) By Instruments: Sequencing Systems; Sample Preparation Systems; Detection And Imaging Systems; Automation And Robotics Systems; Data Analysis Hardware 2) By Consumables: Sequencing Reagents; Library Preparation Kits; Sample Collection Kits; Flow Cells; Quality Control Reagents

What Is The Driver Of The Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market?

The rising demand for personalized medicine is expected to propel the growth of deoxyribonucleic acid (DNA) sequencing in the drug discovery market going forward. Personalized medicine refers to a medical approach that tailors disease prevention, diagnosis, and treatment to an individual’s genetic makeup, lifestyle, and environmental factors. Rising demand for personalized medicine is primarily due to advances in genomics and molecular diagnostics, which enable precise identification of genetic and molecular differences among individuals, allowing treatments to be tailored for improved effectiveness and reduced side effects. Deoxyribonucleic acid (DNA) sequencing helps personalized medicine by identifying patient-specific genetic variations that enable the development of targeted therapies, optimized drug selection, and improved treatment efficacy with reduced adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the rising demand for personalized medicine is driving the growth of deoxyribonucleic acid (DNA) sequencing in the drug discovery market.

Key Players In The Global Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market

Major companies operating in the deoxyribonucleic acid (dna) sequencing in drug discovery market are Thermo Fisher Scientific Inc., Eurofins Genomics GmbH, Agilent Technologies Inc., Illumina Inc., Revvity Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., 10x Genomics Inc., BGI Genomics, Azenta Life Sciences, Oxford Nanopore Technologies plc, Pacific Biosciences of California Inc., Element Biosciences Inc., Macrogen Inc., Ultima Genomics Inc., SOPHiA GENETICS SA, ProPhase Labs Inc., Singular Genomics Systems Inc., Psomagen Inc., and QitanTech Co Ltd.

Global Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Trends and Insights

Major companies operating in the deoxyribonucleic acid (DNA) sequencing in the drug discovery market are focusing on developing advanced solutions, such as high-resolution DNA methylation sequencing assays, to accelerate biomarker discovery and precision drug development. High-resolution DNA methylation sequencing assays are sophisticated genomic methods that accurately profile DNA methylation at single-base or near single-base resolution across the genome, allowing in-depth evaluation of epigenetic changes to control gene activity, aiding precise understanding of disease biology and identification of potential drug targets. For instance, in April 2025, EpiCypher Inc., a US-based epigenetics company, launched CUTANA mCUT&RUN and Multiomic CUT&RUN, two innovative DNA methylation sequencing assays designed to provide high-resolution methylation profiling with significantly lower sequencing costs and sample input requirements. These assays enable researchers to simultaneously analyze DNA methylation and chromatin features, offering deeper multiomic insights into gene regulation mechanisms. These assay advancements support faster and more cost-effective target identification and validation, thereby accelerating drug discovery and development.

What Are Latest Mergers And Acquisitions In The Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market?

In May 2025, Mapmygenome India Pvt. Ltd., an India-based provider of AI-driven genomics and personalized health solutions, acquired Microbiome Insights for an undisclosed amount. With this acquisition, Mapmygenome aims to expand its scientific and sequencing capabilities in microbiome research and accelerate its North American market entry while broadening its integrated genomics and microbiome service offerings. Microbiome Insights Inc. is a Canada-based company that provides deoxyribonucleic acid (DNA) sequencing services specifically designed for drug discovery, development, and clinical trials in the pharmaceutical and biotechnology sectors.

Regional Insights

North America was the largest region in the deoxyribonucleic acid (DNA) sequencing in drug discovery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market?

The deoxyribonucleic acid (DNA) sequencing in the drug discovery market includes revenues earned by entities through next-generation sequencing services, whole genome sequencing services, whole exome sequencing services, targeted sequencing services, Sanger sequencing services, and single-cell sequencing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Report 2026?

The deoxyribonucleic acid (dna) sequencing in drug discovery market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the deoxyribonucleic acid (dna) sequencing in drug discovery industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.